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Abstract
Background: Twenty to 30 percent of all transient ischaemic attacks and ischaemic strokes involve tissue supplied by the
vertebrobasilar circulation. Atherosclerotic stenosis ≥ 50% in the vertebral artery accounts for vertebrobasilar stroke in at least
one third of the patients. The risk of recurrent vascular events in patients with vertebral stenosis is uncertain and
revascularisation of vertebral stenosis is rarely performed. Observational studies have suggested that the risk of subsequent
stroke or death in patients with vertebrobasilar ischaemic events is comparable with that in patients with carotid territory
events. Treatment of vertebral stenosis by percutaneous transluminal angioplasty has been introduced as an attractive treatment
option. The safety and benefit of stenting of symptomatic vertebral stenosis as compared with best medical therapy alone
remains to be elucidated in a randomised clinical trial.
Study objectives: The primary aim of the Vertebral Artery Stenting Trial (VAST) is to assess whether stenting for symptomatic
vertebral artery stenosis ≥ 50% is feasible and safe. A secondary aim is to assess the rate of new vascular events in the territory
of the vertebrobasilar arteries in patients with symptomatic vertebral stenosis ≥ 50% on best medical therapy with or without
stenting.
Design: This is a randomised, open clinical trial, comparing best medical treatment with or without vertebral artery stenting in
patients with recently symptomatic vertebral artery stenosis ≥ 50%. The trial will include a total of 180 patients with transient
ischaemic attack or non-disabling ischaemic stroke attributed to vertebral artery stenosis ≥ 50%. The primary outcome is any
stroke, vascular death, or non-fatal myocardial infarction within 30 days after start of treatment. Secondary outcome measures
include any stroke or vascular death during follow-up and the degree of (re)stenosis after one year.
Discussion:  Improvements both in imaging of the vertebral artery and in endovascular techniques have created new
opportunities for the treatment of symptomatic vertebral artery stenosis. This trial will assess the feasibility and safety of stenting
for symptomatic vertebral artery stenosis and will provide sufficient data to inform a conclusive randomised trial testing the
benefit of this treatment strategy. The VAST is supported by the Netherlands Heart Foundation (2007B045; ISRCTN29597900).
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Background
Twenty to 30 percent of all transient ischaemic attacks
(TIA's) and ischaemic strokes involve tissue supplied by
the vertebrobasilar (VB) circulation [1,2]. The vertebral
and basilar arteries feed the brain stem, cerebellum, and
thalamus, and in most people the posterior temporal and
occipital lobes as well. In a large American registry of pos-
terior circulation stroke, 22% of the patients with VB TIA
or stroke had a poor functional outcome at 30 days [3].
However, some forms of VB ischaemia have a more relent-
less course. Occlusion of the basilar artery, for example, is
associated with death or dependence in almost 80% of the
cases [4].
Common causes of VB ischaemia are embolism from the
heart or large arteries, or small-vessel disease [2]. In the
above-mentioned registry, 32% of the ischaemic events
were presumed to be caused by haemodynamic mecha-
nisms [3]. Atherosclerotic stenosis ≥ 50% at the origin of
the vertebral artery or in its intracranial course were both
found in about one third of the patients.
In contrast to carotid stenosis, there has been little system-
atic research into the prognosis and the prevention of
recurrent vascular events in patients with vertebral artery
stenosis. In the carotid surgery trials, patients with ≥ 50%
symptomatic carotid stenosis randomised to medical
treatment alone had a 5-year risk of ipsilateral carotid
ischaemic stroke of 21.2% (95% CI, 18.8 – 23.6) [5]. Sim-
ilar data are not available for symptomatic vertebral artery
stenosis. The best available data come from a systematic
review of all published studies of prognosis after VB TIA or
minor stroke, in which the risk of subsequent stroke or
death in patients with VB events was similar to the risk in
patients with carotid territory events [1].
In patients with carotid stenosis of 50% or greater, carotid
endarterectomy (CEA) leads to an absolute reduction in
the 5-year cumulative risk of ipsilateral carotid ischaemic
stroke and any stroke or death within 30 days after surgery
of 8.5% (95% CI, 5.6 – 11.3) [5]. Two large randomised
clinical trials are currently studying carotid stenting as an
alternative to CEA. Based on large case series, it is hypoth-
esized that the trials will demonstrate the equivalence of
carotid stenting as compared with CEA. By contrast, the
benefit of revascularisation of vertebral stenosis is fully
uncertain. Surgery to this artery is difficult due to poor
access and is not considered in most centres [6]. In the last
decade, treatment of vertebral stenosis by percutaneous
transluminal angioplasty, usually with stent placement,
has been introduced as an attractive alternative to surgery.
The endovascular access to the vertebral artery is relatively
easy and the procedure can be performed without general
anaesthesia, enabling continuous neurological monitor-
ing of the patient. However, the procedure also has disad-
vantages. The major risk of endovascular treatment is
dislodgement and distal embolisation of plaque and
thrombotic debris, which may lead to stroke. In a recent
review of reports on 331 endovascular treatments of ver-
tebrobasilar stenosis, the 30-day risk of TIA, stroke, or
death was 6.4% [6]. In another review of stenting proce-
dures for vertebral or basilar artery stenosis reported up to
2005, the periprocedural risk of stroke or death was 1.6%
for proximal vertebral artery stenosis and 13.8% for distal
VB stenosis [7]. After a mean follow-up of one year, reste-
nosis had occurred in one quarter of the cases of proximal
vertebral artery stenting. The difference in complication
rates in the treatment of proximal versus distal vertebral
artery stenosis is most likely the result of several factors.
First, studies of distal VB artery stenosis included lesions
of the basilar artery as well. In addition, the distal proce-
dures were much more frequently performed in the acute
phase of VB artery thrombosis, and antithrombotic treat-
ment strategies were different. For this reason, there are no
reliable data on stenting of the distal vertebral artery after
the acute phase.
Case series are prone to publication bias and the percent-
ages reported above may be different in daily clinical prac-
tice. The combined 30-day incidence of any stroke or
death in randomised trials on carotid stenting versus CEA,
was 8.2% (126/1492) after stenting [8]. Moreover, the
interpretation of outcome results after vertebral stenting is
complicated by the lack of data on the risk of recurrent
stroke in patients with vertebral stenosis on best medical
therapy alone. Most importantly, the only trial that has
compared endovascular treatment with medical therapy
in a randomised fashion, included just 16 patients [6,9].
In conclusion, stenting of vertebral artery stenosis appears
a promising technique for the prevention of recurrent vas-
cular events in the VB territory, but is still without a
proven benefit. The procedure may be complicated by dis-
abling stroke and early restenosis. Before widespread
application, the procedure should be assessed in a large
randomised trial. As a prelude to such a trial, the present
study aims to determine the safety and feasibility of stent-
ing for symptomatic vertebral artery stenosis.
Study objectives
The present study aims to determine whether stenting for
symptomatic vertebral artery stenosis ≥ 50% in patients
with a recent transient ischaemic attack or minor disa-
bling ischaemic stroke in the posterior circulation is feasi-
ble and safe. In addition, the rate of new vascular events
in the territory of the vertebrobasilar arteries will be
assessed in patients with symptomatic vertebral artery ste-
nosis ≥ 50% who receive best medical treatment or best
medical treatment combined with endovascular therapy.Trials 2008, 9:65 http://www.trialsjournal.com/content/9/1/65
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The results will serve to design a large and conclusive ran-
domised clinical trial in which stenting plus best medical
treatment will be compared to best medical treatment
alone in patients with symptomatic vertebral artery steno-
sis.
Study design
This is a randomised, open, multi-centre clinical trial with
masked outcome assessment, comparing the combina-
tion of vertebral artery stenting and best medical treat-
ment with best medical treatment alone in patients with a
recently symptomatic stenosis of a vertebral artery of at
least 50%. A total of 180 patients will be included. Fol-
low-up will continue until one year after inclusion of the
last patient.
Endovascular treatment will be performed by an experi-
enced interventional radiologist with a track record of at
least 50 interventions in the carotid or vertebral arteries in
the last 5 years. The procedure will include percutaneous
transluminal angioplasty followed by stenting. The type
of stent and the use of a protection device will be left to
the discretion of the interventionist. If stent placement is
not feasible or deemed contra-indicated, angioplasty
without stent placement will be performed. The proce-
dure will be performed under local anaesthesia, with con-
tinuous monitoring of heart rhythm and blood pressure.
All patients randomised to stenting will receive clopidog-
rel 75 mg daily starting at least five days before the proce-
dure and continued for 30 days after the procedure.
Patients not on clopidogrel the day before the procedure
should be loaded with 300 mg clopidogrel at least six
hours before stenting. Best medical treatment will be left
to the discretion of the neurologist, but should include
rigorous control of vascular risk factors, the use of
antiplatelet agents, and the use of a statin.
Enrolment criteria
Patients can be enrolled in the study if the following crite-
ria have been met:
1. TIA or non-disabling ischaemic stroke of the posterior
circulation;
2. symptoms occurred in the 180 days preceding ran-
domisation;
3. possibility to perform stenting within two weeks after
randomisation;
4. stenosis of the vertebral artery of 50% or greater, diag-
nosed by both duplex ultrasound and CT angiography
(CTA), contrast-enhanced MR angiography (MRA), or
conventional angiography, and presumed to be of athero-
sclerotic origin and accessible for endovascular treatment;
5. score on the modified Rankin scale ≤ 3 (independent in
daily activities, although some help may be needed) [10];
6. age 40 years or older;
7. written informed consent.
Patients will be excluded from the study in case of
1. a potential cause of TIA or minor stroke other than ste-
nosis in a vertebral artery (e.g. atrial fibrillation);
2. a vertebral artery stenosis caused by arterial dissection;
3. previous surgical or endovascular treatment of the sten-
osis;
4. a life expectancy shorter than three years;
5. another serious illness that may confound outcome
assessment;
6. severe renal impairment, precluding contrast adminis-
tration;
7. allergy to iodinated contrast agent;
8. pregnancy.
Posterior cerebral artery TIA or infarct
In the majority of patients, blood supply via the posterior
cerebral artery (PCA) to the occipital lobes is through the
VB circulation. However, in a substantial portion of
patients the PCA is fully supplied by the carotid artery
instead of the VB arteries [11]. For this reason, we will
assess the presence of an ipsilateral P1 segment of the PCA
and of an ipsilateral posterior communicating artery on
the initial MRA, CTA, or conventional angiography in all
patients with (transient) ischaemia in the territory of the
PCA. In case of uncertainty about the supply of the PCA,
direction of flow in the posterior communicating artery
will be assessed, for example by means of transcranial
Doppler sonography. Of the patients with ischemia in the
PCA territory only, those with an exclusive supply of the
PCA via the carotid artery will be excluded.
Randomisation
A total of 180 patients will be included in the study.
Patients will be randomised to either the combination of
vertebral artery stenting and best medical treatment or
best medical treatment alone with use of a web-based ran-
domisation system, which includes a minimisation algo-
rithm [12]. Randomisation will be stratified by centre and
location of the stenosis (origin vs. more distal parts of the
vertebral artery).Trials 2008, 9:65 http://www.trialsjournal.com/content/9/1/65
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Outcome assessment
Clinical outcome assessment will be performed by three
independent adjudicators on the basis of an anonymised
written description of the outcome event and ancillary
investigations. This description will be made by the
research physician in such a way that the adjudicators will
remain masked to the allocated treatment.
The primary outcome measure will be vascular death,
non-fatal myocardial infarction, or non-fatal stroke (neu-
rological deficit lasting longer than 24 hours for which no
other cause than a stroke can be found) within 30 days
after start of the treatment (see Appendix for definitions).
Secondary outcome measures will be vascular death, non-
fatal myocardial infarction, or non-fatal stroke during fol-
low-up. Other outcome measures include any stroke in
the supply territory of the symptomatic vertebral artery
during follow-up and the degree of stenosis of the symp-
tomatic vertebral artery after one year, as assessed with
both Duplex ultrasound and CT angiography.
Data collection
At baseline, medical history (including clinical signs and
symptoms, duration of the neurological deficit, number
of attacks, previous cardiovascular events, previous cardi-
ovascular treatments, vascular risk factors, and medica-
tion) will be assessed and clinical and neurological
examination (including blood pressure) will be carried
out. The baseline neurological and functional status will
be assessed with the National Institutes of Health Stroke
Scale (NIHSS) and with the modified Rankin Scale
[10,13]. The vascular risk factors (hypertension, smoking,
diabetes, lipid disorders) will be noted. Laboratory inves-
tigations will include complete blood count, erythrocyte
sedimentation rate, C-reactive protein, and cholesterol.
The degree of stenosis in the vertebral artery will be
assessed with duplex ultrasound and MRA, CTA, or con-
ventional angiography. Except for duplex ultrasound, the
degree of the stenosis will be calculated by dividing the
residual lumen (N) by vessel diameter at a point distal to
the stenosis where the normal vessel calibre has been
restored (D), and applying the formula: (1 - N/D) × 100%
= degree of stenosis [14]. To assess the location of steno-
sis, the vertebral artery is divided into four sections: V1-V3
form the extracranial vertebral artery and V4 forms the
intracranial vertebral artery [15]. The type of plaque in the
vertebral artery and the presence and degree of stenosis in
other brain feeding arteries will be noted.
CT and MRI scans will be performed to investigate the
presence and type of a cerebral infarct (supply territory of
intracerebral artery, small vessel disease, large vessel dis-
ease)
Follow-up
Follow-up visits will be performed at one day and at 1, 6,
and 12 months after stenting (or randomisation in the
conservative treatment group) and every year thereafter.
The close-out visit of each patient will be scheduled one
year after randomisation of the last patient.
Follow-up data to be obtained at one day and after 1, 6
and 12 months, every year thereafter, and at close out will
include:
1. the occurrence and type of vascular event;




5. score on the modified Rankin Scale;
6. the degree of (re)stenosis assessed with duplex ultra-
sound and CTA will be assessed after one year and follow-
ing an ischaemic stroke.
Statistical considerations
With 90 patients in the endovascular intervention arm, a
complication rate of 7.8% (7 events) would yield a 95%
confidence interval from 3.2 to 15.4%. The estimate of
7.8% is comparable to that of 8.2% for carotid stenting
[8]. As the number of patients receiving angioplasty with-
out stent placement is expected to be extremely small,
these patients will be analysed together with the patients
who have received a stent.
Inclusion of a total of 90 patients in the medical arm dur-
ing three years and one final year of follow up for these
patients will provide 225 patient years of follow up. This
number of patient years would yield a 95% confidence
interval of 4.1 to 11.5% for an annual event rate of 7%.
An additional analysis will be done to compare the inci-
dence of vascular events between the two treatment
groups. This analysis will be based on the intention-to-
treat principle and reported in terms of the hazard ratio
with corresponding 95% confidence intervals calculated
with the Cox proportional hazard model.
We consider the precision of the above estimates suffi-
cient for reliable calculation of the sample size of a con-
clusive randomised clinical trial.
Safety and indemnity
The major risk of endovascular treatment is dislodgement
and distal embolisation of plaque and thrombotic debris,Trials 2008, 9:65 http://www.trialsjournal.com/content/9/1/65
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which may lead to stroke. In a recent review of reports on
331 endovascular treatments of VB artery stenosis, the 30-
day risk of TIA, stroke, or death was 6.4% [6]. In another
review of stenting procedures for vertebral or basilar artery
stenosis reported up to 2005, the periprocedural risk of
stroke or death was 1.6% for proximal vertebral artery ste-
nosis and 13.8% for distal artery stenosis [7]. Other neu-
rological complications, such as vertebral artery
dissection, occurred in 2.6% and 6.0% of the cases,
respectively, and non-neurological complications, such as
inguinal haematoma, in 1.3% and 2.8%. As mentioned
above, the complication rates for distal VB stenting do
probably not apply to stenting of the distal vertebral artery
outside the acute phase of posterior circulation ischaemia.
After a mean follow-up of one year, restenosis has been
reported to occur in one quarter of the cases of proximal
vertebral artery stenting. However, case series are prone to
publication bias and the percentages reported may be dif-
ferent in daily clinical practice. In all randomised trials on
carotid stenting versus CEA, the 30-day incidence of any
stroke or death was 8.2% (126/1492) after stenting [8].
Moreover, a limitation in interpreting data on vertebral
artery stenting is the absence of data describing the risk of
recurrent stroke in patients with vertebral stenosis on best
medical therapy alone.
Ethical considerations
The study will be conducted according to the principles of
the Declaration of Helsinki, as amended in 2000 and clar-
ified in 2004, and in accordance with the Dutch Medical
Research Involving Human Subjects Act (WMO).
Approval by the local medical ethical review board is
required for each participating centre before start of
patient inclusion. The patients will be informed about the
trial by their treating physician but will whenever possible
be asked for consent by a physician not involved in their
treatment. Patients should reach a decision about partici-
pation within 180 days after the last vertebrobasilar symp-
tom.
The trial compares two existing forms of treatment cur-
rently used in many hospitals worldwide. The investiga-
tors anticipate that some patients may be harmed
inadvertently as a result of either the stenting procedure or
the decision to refrain from invasive treatment. The deter-
mination of the rate of these adverse outcome events is in
fact the major aim of the trial. In the majority of patients
with a recently symptomatic carotid stenosis of 50% or
greater, CEA reduces the long-term risk of stroke despite
the risks of the intervention [5,14] but at present it is
unknown whether this also applies to stenting of vertebral
artery stenosis. The trial protocol does not subject patients
to hazards that would not have been encountered if they
had received the trial treatments outside the context of the
trial in routine clinical practice, except for the very small
chance of a complication of CTA performed one year after
start of treatment, such as an allergic reaction or contrast
nephropathy. Individual investigators and hospitals are
required to take responsibility for the occurrence of any
adverse events in the same way as they would do if the
treatments were performed outside the trial.
The sponsor/investigator has a liability insurance which is
in accordance with article 7, subsection 6 of the WMO.
The sponsor (also) has an insurance which is in accord-
ance with the legal requirements in the Netherlands (Arti-
cle 7 WMO and the Measure regarding Compulsory
Insurance for Clinical Research in Humans of 23 June
2003). This insurance provides coverage for damage to
research subjects through injury or death caused by the
study.
Adverse event reporting
An adverse event is any unfavourable and unintended sign,
symptom, or disease occurring during the follow-up
period of the study. Adverse events occurring after ran-
domisation will be recorded on the adverse event page of
the CRF.
A serious adverse event is defined as any adverse event that
results in:
1. death;
2. a life-threatening condition;
3. inpatient hospitalisation or prolongation of existing
hospitalisation;
4. persistent or significant disability/incapacity.
An important medical event that may not result in one of the
above conditions may be considered a serious adverse
event when, based upon medical judgement, it may jeop-
ardise the patient and may require medical or surgical
intervention to prevent one of the outcomes above. A rea-
sonably related adverse event is defined as one that is possi-
bly, probably, or definitely related to the trial treatment.
All serious adverse events occurring within 30 days after
stenting (or within 30 days after randomisation in the
conservative treatment group) and adverse events that are
serious and reasonably related to the trial treatment but
occur after the first 30 days require completion of the
safety report, which should be sent to the trial co-ordina-
tion centre within 5 working days of observation or noti-
fication of the event. All serious adverse events not related
to trial treatment during follow-up require completion of
the safety report at the planned follow-up visits.Trials 2008, 9:65 http://www.trialsjournal.com/content/9/1/65
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Each outcome event will be reported to the Data Monitor-
ing and Safety Committee (DMSC). We propose the
DMSC to use the lower limit of the 95% confidence inter-
val of the complication rate as a criterion to advice the
Steering Committee to stop the trial. This lower limit
should not be higher than 8.2%, the rate reported for
carotid artery stenting. Moreover, we will ask the DMSC to
perform one interim analysis halfway during the trial, i.e.
after one half of the planned patient-years have been
accrued. For this interim analysis we propose the simple 3
standard deviation stopping rule proposed by Peto, that
essentially advises to stop at p < 0.001 [16]. We consider
it highly unlikely, however, that this threshold will be
reached in our relatively small feasibility study.
Publication of the trial results
The trial results will be published by the members of the
Steering Committee, on behalf of the investigators.
Discussion
We present the protocol of a randomised clinical trial
designed to test the safety and feasibility of vertebral artery
stenting in patients with a symptomatic stenosis ≥ 50% of
a vertebral artery. Case reports suggest that vertebral artery
stenting is relatively safe with a periprocedural risk of
stroke or death ranging from 1.6 to 13.8%.
In a recent review, stenting of the extracranial vertebral
artery in 313 patients resulted in technical success in 98 to
100% of the cases, with a 0.3% risk of death and 5.5% risk
of neurological complications [7]. Stenting of the distal
(intracranial) vertebral artery in 283 patients was associ-
ated with technical success in 97 to 98%, but with higher
complication rates: a case fatality rate of 3.2% and a
17.3% risk of neurologic complications. The differences
in complication rates of stenting between the proximal
and distal vertebral artery may be explained by the fact
that stenting of the distal vertebral artery was more fre-
quently performed in the acute phase of vertebral or basi-
lar occlusion and was considered technically more
difficult.
The interpretation of outcome after vertebral stenting is
complicated by the lack of data on the risk of recurrent
stroke in patients with vertebral stenosis on best medical
therapy alone. To date no reliable data are available on the
prognosis of VB stroke. In a recent review, the risk on
recurrent stroke in the acute phase (up to seven days) is
considered probably higher in patients presenting with a
VB event compared with patients presenting with carotid
events [1].
Stenting of the proximal vertebral artery might be associ-
ated with a relatively high rate of restenosis at follow-up.
In the above-mentioned review, restenosis of the proxi-
mal vertebral artery has been reported in a quarter of the
cases after a mean follow-up of 11.8 months [7]. The def-
inition of restenosis varied for the different studies. Detec-
tion criteria included maximal flow velocity in the
stenosis in relation to prestenotic or poststenotic seg-
ments, pulsatility, anterograde or retrograde direction of
flow, and the presence of end-diastolic flow signal proxi-
mal to the lesion on duplex ultrasound. Restenosis in the
distal vertebral artery was detected in about one fifth of
the cases after a mean follow-up of 7.5 months. Most of
the patients with restenosis remained asymptomatic. It
has been suggested that neointimal proliferation follow-
ing stent placement has a lower risk on thromboembolic
events than atherosclerosis [17]. Possible predictors for
restenosis are high age, low pre-treatment vessel diameter
and post-treatment stenosis [7,18,19].
Since the natural course of a symptomatic vertebral artery
stenosis in patients on best medical treatment alone is
unknown and the exact indications for vertebral stenting
are unclear a randomised clinical trial is needed. By com-
paring outcome in patients on best medical treatment
alone and patients with vertebral artery stenting, a conclu-
sion can be drawn on the safety and feasibility of vertebral
artery stenting in symptomatic vertebral artery stenosis.
Conventional angiography is the gold standard for the
diagnosis of vertebral artery stenosis. Randomisation to
either stenting or best medical treatment in this study will
take place before angiography is performed. It is not con-
sidered ethical to perform conventional angiography in
each patient included in the study because this procedure
is associated with a small but inevitable risk of stroke. This
might lead to randomisation of patients to stenting with-
out a significant stenosis on conventional angiography. In
approximately half of the patients (patients randomised
to best medical treatment alone), grading of the stenosis
will be done on the basis of CTA or MRA and duplex ultra-
sound alone. Studies of sufficient quality validating the
accuracy of diagnosing and grading vertebral artery steno-
sis with non-invasive imaging techniques against the gold
standard of intra-arterial angiography are scarce. No stud-
ies have compared the different imaging modalities
against intra-arterial angiography in the same cohort of
patients. Contrast-enhanced MRA and possibly CTA may
be more sensitive in diagnosing vertebral artery stenosis
than duplex ultrasound [20].
The trial has started 1 June 2008 in two centres in the
Netherlands. Four other Dutch centres are expected to
join the trial shortly. Other centres, also from other coun-
tries than the Netherlands, that have adequate experience
with the management of vertebral artery stenting are wel-
come to participate.Trials 2008, 9:65 http://www.trialsjournal.com/content/9/1/65
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Trial organisation
Steering committee
The Steering Committee carries the ultimate responsibil-
ity for the trial. Specific tasks of the steering Committee
are:
1. approval of the study protocol;
2. approval of amendments to the study protocol;
3. deciding whether or not to continue the trial based on
the recommendations of the DMSC;
4. reviewing protocols for satellite studies;
5. approval of reports and publications of the trial.
The Steering Committee is constituted of the principal
investigators of each actively randomising centre, and of
the members of the executive committee.
As of 20 July 2008, members of the Steering Committee
are (in alphabetical order): A. Algra,* clinical epidemiolo-
gist, University Medical Centre, Utrecht – A. Compter,*
research physician, University Medical Centre, Utrecht –
L.J. Kappelle,* neurologist, University Medical Centre,
Utrecht, co-principal investigator – T.H. Lo, interven-
tional radiologist, University Medical Centre, Utrecht –
W.P.Th.M. Mali, radiologist, University Medical Centre,
Utrecht – F.L. Moll, vascular surgeon, University Medical
Centre, Utrecht – W.J. Schonewille,* neurologist, St.
Antonius Hospital, Nieuwegein – J.A. Vos,* radiologist,
St. Antonius Hospital, Nieuwegein – H.B. van der Worp,*
neurologist, University Medical Centre, Utrecht, co-prin-
cipal investigator. The members of the Executive Commit-
tee, who are responsible for the trial on a day-to-day basis,
are marked with an asterisk.
Trial Coordination Centre
The Trial Co-ordination Centre is located at the Trial
Office Neurology of the Department of Neurology of the
University Medical Centre, Utrecht, The Netherlands. The
centre will be staffed by the trial co-ordinator and a data
manager.
Data Monitoring and Safety Committee
The DMSC performs analyses of the unblinded data on a
permanent basis and formulates recommendations for
the Steering Committee on the continuation of the trial.
The Data Monitoring Committee may also offer unsolic-
ited recommendations.
Members of the Data Monitoring Committee are being
sought.
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Appendix. definitions of vascular complications
1. Death from vascular causes:
a. Fatal cerebral infarction: cerebral infarction causing an
increase of handicap to Rankin 4 or 5, followed by death.
Death should have been an unlikely event without the
preceding infarction.
b. Fatal cerebral hemorrhage: cerebral haemorrhage caus-
ing an increase of handicap to Rankin 4 or 5, followed by
death. Death should have been an unlikely event without
the preceding bleeding.
c. Fatal myocardial infarction: Documented myocardial
infarction (see 6) followed by death, at least one hour
after onset of symptoms.
d. Definite sudden death: witnessed sudden death with
reliable observation of timing; i.e. patient died within one
hour after onset of symptoms.
e. Probable sudden death: witnessed death, but unreliable
data on timing of events, or found dead and previously
"healthy."
f. Terminal heart failure.
g. Fatal arterial bleeding.
h. Other fatal vascular complication, e.g. gastric bleeding,
pulmonary embolism.
2. Cerebral infarction.
a. Definite new cerebral infarction: clinical evidence of the
sudden onset of a new neurological deficit, persisting forPublish with BioMed Central    and   every 
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more than 24 hours, with a corresponding new infarct on
a repeat CT scan.
b. Probable new cerebral infarction: clinical evidence of
the sudden onset of a new neurological deficit, or an
increase in an existing deficit, persisting for more than 24
hours, without a new infarct on repeat CT scan.
3. Intracerebral haemorrhage
a. Clinical evidence of a sudden new neurological deficit,
or an increase in an existing deficit, persisting for more
than 24 hours, with a corresponding cerebral haemor-
rhage on a CT or MRI scan.
4. Subarachnoid haemorrhage
a. A sudden unusual headache and/or a reduction in con-
sciousness with a corresponding subarachnoid haemor-
rhage on CT or MRI, or signs of subarachnoid
haemorrhage in the cerebrospinal fluid.
5. Unspecified stroke
a. Clinical evidence of a sudden new neurological deficit,
or an increase in an existing deficit, persisting for more
than 24 hours, with no imaging performed.
6. Myocardial infarction
a. Myocardial infarction: At least two of the following
characteristics have to be documented: a history of chest
discomfort for at least half an hour, specific cardiac
enzymes more than twice the upper limit of normal, or
the development of specific abnormalities (e.g. Q waves)
on the standard 12-lead electrocardiogram.
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